Sarepta at new high on eteplirsen, Prosensa's drisapersen data
This article was originally published in Scrip
Executive Summary
Exactly one year after Sarepta Therapeutics saw its value triple based on 48-week, Phase II clinical trial data for its Duchenne muscular dystrophy (DMD) drug, the company's stock price reached a new high on 3 October based on the latest six-minute walk test (6MWT) and dystrophin results for eteplirsen and the competing DMD therapy drisapersen.